• Explore /
  • Poster
  • / ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).

ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).

Abstract Poster

Authors

null

Hailiang Zhang

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

Hailiang Zhang , Yiping Zhu , Ding-Wei Ye

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

ChiCTR2200063085

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4612)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4612

Abstract #

TPS4612

Poster Bd #

98b

Abstract Disclosures

Similar Posters

First Author: Guru P. Sonpavde

First Author: Michal Sternschuss

First Author: yueyun chen

First Author: Changying Guo